Generalized epilepsy has traditionally been considered a seizure of the "'whole brain.'" However, new research has challenged this longstanding idea, since carefully targeting specific brain areas ...
Frederic L.W.V.J. Schaper, MD, PhD, director of Epilepsy Network Mapping at the Center for Brain Circuit Therapeutics at Brigham and Women’s Hospital and an instructor of neurology at Harvard Medical ...
Neuroimaging has transformed our understanding of generalized epilepsy syndromes, revealing that they arise from the dynamic interplay of widespread brain networks rather than isolated foci. Advances ...
People with generalized epilepsy who have seizures arising from both sides of the brain simultaneously, have a higher risk of obstructive sleep apnea (OSA) compared to patients who have focal epilepsy ...
LONDON--(BUSINESS WIRE)-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that 24-month data on generalized tonic-clonic (GTC) seizures in people with ...
-- New approval for VIMPAT® (lacosamide) CV in the U.S. as adjunctive therapy in the treatment of primary generalized tonic-clonic seizures (PGTCS) in patients four years of age and older -- All three ...
-- Company received communication from FDA indicating that the PMA Supplement for idiopathic generalized epilepsy is not approvable in its current form and that additional clinical evidence from the ...
Ono Pharma receives manufacturing & marketing approval in Japan for Xcopri tablets to treat patients with partial-onset seizures, with or without secondary generalized seizures: O ...
Valproate (Depakene) emerged as the best first-line choice for generalized epilepsy in a pragmatic study and lamotrigine (Lamictal) as the best first-line treatment for focal epilepsy, British ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results